Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

LifeRx.md has chosen to extend its Black Friday pricing through the New Year, creating accessibility for a range of treatment options. For the remainder of the year, the company’s GLP-1 and GIP weight ...

The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

"All of this stuff just scares the crap out of me." The post People Jabbing Themselves With Black Market “GLP-3” Drugs ...

VANCOUVER, BC / ACCESS Newswire / December 11, 2025 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent ...

RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the ...

PHOENIX -- Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major cardiovascular events compared with semaglutide (Ozempic, Wegovy) ...

LifeRx.md announced that it has implemented reduced pricing for its personalized GLP-1 and GIP treatment programs, a development the organization states is intended to align with the federal ...

CMS released plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. The announcement comes weeks following the White House’s ...

In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week ...

VANCOUVER, BC / ACCESS Newswire / December 10, 2025 / Lir Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new comparative ...

Researchers believe they may have the next, better version of Ozempic in the works. At Tufts University, scientists have developed a new drug that aims to boost weight loss while also reducing the ...